Exelixis, Inc. (NASDAQ:EXEL)
CAPS Rating:
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Recs
I still cannot believe this dropped so significantly due to two deaths in the trials. XL-184 will be approved and this stock will skyrocket, if it isn't bought out before then.